• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » CDER Issues Guidance Agenda for 2022 Featuring Clinical Trials

CDER Issues Guidance Agenda for 2022 Featuring Clinical Trials

February 14, 2022

The FDA’s Center for Drug Evaluation and Research’s (CDER) guidance agenda for 2022 includes eight draft guidances for clinical trials the center hopes to release before the end of the year.

Topics of trial-related draft guidances on the list include:

  • Decentralized clinical trials;
  • Using clinical practice data in randomized controlled trials for drugs and biologics;
  • Considerations for designing and conducting externally controlled trials for drugs and biologics;
  • Determining good cause for noncompliance on periodic status reports required in certain cases for postmarketing studies and clinical trials;
  • Inborn errors of metabolism that use dietary management: considerations for optimizing and standardizing diet in clinical trials for drug product development;
  • Measuring growth and evaluating pubertal development in pediatric clinical trials;
  • Meeting the substantial evidence standard based on one adequate and well-controlled clinical investigation and confirmatory evidence; and
  • Use of data monitoring committees in controlled clinical trials.

The annual guidance agenda is more of a wish list for the year than a firm commitment by the center. Five of the eight trial-related draft guidances on this year’s list are carryovers from 2021. The list does not include any final trial-related guidances CDER plans to issue in 2022.

Read the 2022 FDA guidance agenda here: https://bit.ly/3LlPOxJ.

 

To view more CenterWatch Weekly stories, click here.

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing